Granted Patent B2

US 11,730,803 · App. 17/680,813 · Granted Aug 22, 2023

Inventors: Nicole F. Steinmetz (Cleveland, OH); Amy M. Wen (Cleveland, OH); Steven Fiering (Hanover, NH); Patrick H. Lizotte (Cleveland, OH)

Assignees: CASE WESTERN RESERVE UNIVERSITY; TRUSTEES OF DARTMOUTH COLLEGE

A61K39/12A61K31/704A61P35/00A61P35/04C12N7/00A61K2039/5258A61K2039/544A61K2039/585C12N2770/00023C12N2770/00034C12N2770/00071C12N2770/32022C12N2770/32023C12N2770/32034C12N2770/32071

Abstract

Claims (17)

1. A composition for delivering an active pharmaceutical ingredient directly to a cancer in a subject in need thereof, wherein said composition comprises a pharmaceutically acceptable carrier and therapeutically effective amounts of:

the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is an in situ vaccine that comprises at least one of cowpea mosaic virus or cowpea mosaic virus-like particles, wherein the cowpea mosaic virus and cowpea mosaic virus-like particles are not used as a vehicle for drug or antigen delivery; and

an anticancer agent.

2. The composition of claim 1 , wherein the composition is formulated for intra-tumoral injection.

3. The composition of claim 1 , wherein the composition is formulated as an aerosol.

4. A unit dosage form of a formulation of an in situ vaccine and an anticancer agent; wherein the in situ vaccine comprises at least one of cowpea mosaic virus or cowpea mosaic virus-like particles, wherein the cowpea mosaic virus and cowpea mosaic virus-like particles are not used as a vehicle for drug or antigen delivery.

5. The unit dosage formulation of claim 4 , wherein the in situ vaccine is in association with a liquid carrier or a finely divided solid carrier.

6. The composition of claim 1 , wherein the therapeutically effective amount of the in situ vaccine is an amount effective to stimulate a systemic immune response in the subject.

7. The composition of claim 1 , wherein the in situ vaccine comprises cowpea mosaic virus that includes a nucleic acid, and wherein said nucleic acid is RNA.

8. The composition of claim 1 , wherein the anticancer agent is a chemotherapy or immunotherapy anticancer agent.

9. The composition of claim 8 , wherein the anticancer agent comprises doxorubicin.

10. The composition of claim 8 , wherein the anticancer agent comprises monoclonal antibodies.

11. The unit dosage formulation of claim 4 , wherein the unit dosage form of the in situ vaccine is a dosage effective to stimulate a systemic immune response when administered directly to a cancer in a subject in need thereof.

12. The unit dosage formulation of claim 4 , wherein the in situ vaccine comprises cowpea mosaic virus that includes a nucleic acid, and wherein said nucleic acid is RNA.

13. The unit dosage formulation of claim 4 , wherein the anticancer agent is a chemotherapy or immunotherapy anticancer agent.

14. The unit dosage formulation of claim 13 , wherein the anticancer agent comprises doxorubicin.

15. The unit dosage formulation of claim 13 , wherein the anticancer agent comprises monoclonal antibodies.

Assignments (2)

Continuity (8)